Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Foreign Regulator Exchange Program Contemplated By U.S. State Department

This article was originally published in PharmAsia News

Executive Summary

FDA has its own programs, but a State Department undersecretary said enhancing training at FDA could boost efforts to fight drug counterfeiting and diversion.

You may also be interested in...



Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections

Draft commitment letter could be first step down globalization road in which FDA relies more on foreign governments to boost manufacturing oversight.

Good Neighbors Make Good Regulatory Science Centers, FDA Decides

Georgetown, Maryland gain CERSI grants in part because of their proximity to agency staff.

First FDA Center Of Excellence For Regulatory Science Looks At Nanotechnology

National Center for Toxicological Research signs agreement setting up CERS in Arkansas.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC079278

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel